Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › exenatide

exenatide

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of exenatide

66 trials tracked of exenatide: 48 in phase 3 or 4 and 16 with published results. The most-cited published study has 591 citations.

66Trials tracked
48Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 24 Phase 3 24 Phase 2 7 Phase 1 2 Other / NA 9
  1. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 591 cited
  2. Phase 3 GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin Completed · 254 cited
  3. Phase 4 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women Completed · 157 cited
  4. Phase 3 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Completed · 135 cited
  5. Phase 4 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed · 134 cited
  6. Phase 4 Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes Completed · 109 cited
Show 44 more trials
  1. Phase 3 Role of Exenatide in NASH-a Pilot Study Completed · 107 cited
  2. Phase 4 Acute Effect of Exenatide on Brain Glucose Metabolism Completed · 96 cited
  3. Phase 4 Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes Completed · 85 cited
  4. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Completed · 83 cited
  5. Phase 4 Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying Completed · 78 cited
  6. Phase 3 Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Completed · 78 cited
  7. Phase 4 Weight Loss With Exenatide Treatment Completed · 24 cited
  8. Phase 4 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Completed · 13 cited
  9. Phase 4 Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Completed · 10 cited
  10. Phase 4 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes Completed · 4 cited
  11. Phase 4 Effect of Exenatide on Liver and Heart Fat and Inflammation Completed
  12. Phase 4 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed
  13. Phase 4 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed
  14. Phase 4 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed
  15. Phase 4 Intravenous Exenatide in Patients With Acute Brain Injury Completed
  16. Phase 4 Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia Completed
  17. Phase 4 New Onset Type 1 Diabetes: Role of Exenatide Completed
  18. Phase 4 Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Completed
  19. Phase 4 How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics Completed
  20. Phase 4 Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients Completed
  21. Phase 4 Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione Completed
  22. Phase 4 The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes Completed
  23. Phase 4 Bioenergetic Alterations After Exenatide Administration Completed
  24. Phase 4 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function Completed
  25. Phase 3 Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes Completed
  26. Phase 3 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Completed
  27. Phase 3 Effect on Weight Loss of Exenatide Versus Placebo Completed
  28. Phase 3 A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Completed
  29. Phase 3 Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus Completed
  30. Phase 3 A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients Completed
  31. Phase 3 Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) Completed
  32. Phase 3 Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Completed
  33. Phase 3 Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes Completed
  34. Phase 3 An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes Completed
  35. Phase 3 Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) Completed
  36. Phase 3 Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes Completed
  37. Phase 3 Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin Completed
  38. Phase 3 An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Completed
  39. Phase 3 Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin Completed
  40. Phase 3 A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes Completed
  41. Phase 3 A Study in Participants With Type 2 Diabetes Mellitus Completed
  42. Phase 3 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed
  43. Phase 2 A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients Completed
  44. Phase 2 Exenatide Once Weekly for Smoking Cessation Completed

Showing the 50 most-cited and recently-updated of 66 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes
Nutrition & Obesity Medicine Sys. Review
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes Trial shows different GLP-1 medications impact weight and blood sugar
A network meta-analysis evaluates GLP-1 receptor agonists in adolescents, identifying varying degrees of efficacy across weight, glucose, an…
New analysis of GLP-1 medications shows varying results for weight loss and blood sugar control in adolescents with obesity and type 2 diabe…
Sep 7, 2026
Semaglutide and Phentermine-Topiramate Lead Pediatric Weight Loss
Nutrition & Obesity Medicine Sys. Review
Semaglutide and Phentermine-Topiramate Lead Pediatric Weight Loss Two medications show promise for weight management in children
Network meta-analysis finds semaglutide and phentermine-topiramate most effective for pediatric obesity, with phentermine-topiramate offerin…
New data shows that semaglutide and phentermine-topiramate can help children and teens manage weight when combined with lifestyle changes.
Sep 7, 2026
NT-proBNP and cTnI as Prognostic Biomarkers in Type 2 Diabetes Patients
Cardiology RCT
NT-proBNP and cTnI as Prognostic Biomarkers in Type 2 Diabetes Patients Heart health markers help predict risks for people with diabetes
NT-proBNP serves as a potent predictor of MACE and mortality in T2D patients, while cTnI may identify specific patient subgroups for exenati…
New data shows that specific heart markers can help predict serious heart events and help doctors understand how certain treatments work for…
Sep 3, 2026
Semaglutide and liraglutide are associated with the greatest weight reductions in patients with schizophrenia
Psychiatry Sys. Review
Semaglutide and liraglutide are associated with the greatest weight reductions in patients with schizophrenia New data shows weight loss options for people with schizophrenia
This network meta-analysis of 5898 patients with schizophrenia spectrum disorders evaluated pharmacological interventions for weight reducti…
New data identifies specific medications that help people with schizophrenia manage weight gain while staying on their standard antipsychoti…
Sep 3, 2026
GLP-1 RA exposure in early pregnancy not significantly tied to hypertensive disorders
Diabetes & Endocrinology Meta-analysis
GLP-1 RA exposure in early pregnancy not significantly tied to hypertensive disorders GLP-1 Medications Show No Link to Pregnancy Hypertension Risk
This meta-analysis of observational cohort studies assessed the risk of hypertensive disorders of pregnancy (HDP) after periconceptional or …
A large review of over 10,000 pregnancies suggests that GLP-1 medications may not increase the risk of high blood pressure during pregnancy.
Aug 1, 2026
GLP-1 receptor agonists improve motor function and mood outcomes in patients with Parkinson's disease
Neurology Meta-analysis
GLP-1 receptor agonists improve motor function and mood outcomes in patients with Parkinson's disease GLP-1 medications show promise for Parkinson's disease motor symptoms
This meta-analysis of 850 patients found that GLP-1 receptor agonists significantly improved motor function (SMD -0.21 to -0.32) and mood ou…
New data suggests certain GLP-1 medications may improve movement and mood in people living with Parkinson's disease.
Frontiers Jul 3, 2026
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Nutrition & Obesity Medicine Meta-analysis
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
May 4, 2026
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
Diabetes & Endocrinology Meta-analysis
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA CPAP and weight-loss drugs show different benefits for sleep apnea patients
This network meta-analysis of 3964 adults with obstructive sleep apnea found that CPAP produced the largest reduction in apnea-hypopnea inde…
A large analysis found CPAP best for breathing control, while weight-loss drugs improved body weight and blood sugar levels in sleep apnea p…
May 1, 2026
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
Psychiatry Meta-analysis
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
May 1, 2026
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
May 1, 2026
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Cardiology RCT
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
medRxiv Apr 19, 2026
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Frontiers Apr 12, 2026

All exenatide Articles